Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial

Department of Medicine, Faculty of Medicine, University of Kelaniya0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•1. All consenting male and female adult Naval personnel (18-59.9 years of age)
•2. Exposure to a patient with confirmed COVID-19 infection (rRT-PCR positive for SARS-CoV-2 virus)
•3. The exposure should be for >30 mins within 2 meters of the infected individual and should be within ONE WEEK at the time of inclusion in the study
•4. Recruited within 48 hours of admission to these centers
•5. Willing to take study drug as directed for 5 days.

•1. Pregnant females
•2. Suspected or confirmed to have COVID-19 infection (i.e Navy personnel having positive rRT-PCR test for COVID-19 or presence of fever with cough, shortness of breath, sore throat, anosmia or diarrhoea at the time of recruitment)
•3. Presence of pre-existing cardiovascular disease including being on medication for ischaemic heart disease
•4. Presence of contraindication to the use of HCQ (on other medications predisposing to long QT or presence of long QT on baseline ECG)
•5. Prior diagnosis of retinopathy, G6PD, malignancy or advanced kidney disease
•6. Known sensitivity or allergy to Hydroxychloroquine

发起方

Department of Medicine, Faculty of Medicine, University of Kelaniya